Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1177/1756283X15587481 http://scihub22266oqcxt.onion/10.1177/1756283X15587481 C4530432!4530432!26327920     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Therap+Adv+Gastroenterol 2015 ; 8 (5): 298-312 Nephropedia Template TP {{tp|p=26327920|t=2015. The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment |pdf=|usr=}}{{26327920}} gab.com Text The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment JO: Therap Adv Gastroenterol http://www.kidney.de/pget.php?&tw=1&pmid=26327920 #FOAvip Chronic hepatitis C (CHC) affects over 185 million individuals worldwide, approximately 3% of the world?s population. CHC can lead to quality of life impairment, cirrhosis, hepatocellular carcinoma (HCC), liver failure and liver-related death. While CHC has been associated with increases in HCC, liver-related mortality and all-cause mortality, being cured of CHC is associated with improvement in these outcomes. Older interferon-based regimens were complex and toxic and required 6?12 months of therapy, with cure rates averaging around 40?45% for HCV genotype 1. Newer interferon-free regimens are now available in the US, Europe, Japan and in other countries. These regimens have short durations, minimal side effects, low pill burden and efficacy approaching 90?100%. We may eventually see single-tablet regimens lasting no more than 4?6 weeks. This review will summarize the data regarding these interferon-free regimens, including Gilead?s Harvoni (sofosbuvir/ledipasvir), AbbVie?s Viekira Pak (paritaprevir/ritonavir/ombitasvir with dasabuvir), and Janssen?s Olysio (simeprevir) with sofosbuvir. Some practical considerations as we move into an interferon-free era will also be discussed, such as patient adherence and drug?drug interactions. Twit Text FOAVip The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment ????Therap Adv Gastroenterol http://www.kidney.de/pget.php?&tw=1&pmid=26327920 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26327920 #FOAvip English Wikipedia <ref>{{Cite pmid|26327920}}</ref> The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment #MMPMID26327920 Lam BP; Jeffers T; Younoszai Z; Fazel Y; Younossi ZM Therap Adv Gastroenterol 2015[Sep]; 8 (5): 298-312 PMID26327920show ga Chronic hepatitis C (CHC) affects over 185 million individuals worldwide, approximately 3% of the world?s population. CHC can lead to quality of life impairment, cirrhosis, hepatocellular carcinoma (HCC), liver failure and liver-related death. While CHC has been associated with increases in HCC, liver-related mortality and all-cause mortality, being cured of CHC is associated with improvement in these outcomes. Older interferon-based regimens were complex and toxic and required 6?12 months of therapy, with cure rates averaging around 40?45% for HCV genotype 1. Newer interferon-free regimens are now available in the US, Europe, Japan and in other countries. These regimens have short durations, minimal side effects, low pill burden and efficacy approaching 90?100%. We may eventually see single-tablet regimens lasting no more than 4?6 weeks. This review will summarize the data regarding these interferon-free regimens, including Gilead?s Harvoni (sofosbuvir/ledipasvir), AbbVie?s Viekira Pak (paritaprevir/ritonavir/ombitasvir with dasabuvir), and Janssen?s Olysio (simeprevir) with sofosbuvir. Some practical considerations as we move into an interferon-free era will also be discussed, such as patient adherence and drug?drug interactions. äThe changing landscape of hepatitis C virus therapy: focus on interfer(epmc).pdf DeepDyve Pubget Overpricing